Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 15

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Erectile Dysfunction Drugs Changed the Protein Expressions and Activities of Drug-Metabolising Enzymes in the Liver of Male Rats

Sheweita, Salah A., Wally, Mona, Hassan, Mostafa·2016·Oxidative Medicine and Cellular Longevity
DOI 10.1155/2016/4970906
Open this paper in CoChat — free account

Abstract

Erectile dysfunction (ED) is a major health problem and is mainly associated with the persistent inability of men to maintain sufficient erection for satisfactory sexual performance. Millions of men are using sildenafil, vardenafil, and/or tadalafil for ED treatment. Cytochrome P450s (CYPs) play a central role in the metabolism of a wide range of xenobiotics as well as endogenous compounds. Susceptibility of individuals to the adverse effects of different drugs is mainly dependent on the expression of CYPs proteins. Therefore, changes in activities of phase I drug‐metabolising enzymes [arylhydrocarbon hydroxylase (AHH), dimethylnitrosamine N‐demethylase (DMN‐dI), 7‐ethoxycoumarin‐O‐deethylase (ECOD), and ethoxyresorufin‐O‐deethylase ((EROD)] and the protein expression of different CYPs isozymes (CYP1A2, CYP2E1, CYP2B1/2, CYP3A4, CYP2C23, and CYP2C6) were determined after treatment of male rats with either low or high doses of sildenafil (Viagra), tadalafil (Cialis), and/or vardenafil (Levitra) for 3 weeks. The present study showed that low doses of tadalafil and vardenafil increased DMN‐dI activity by 32 and 23%, respectively. On the other hand, high doses of tadalafil, vardenafil, and sildenafil decreased such activity by 50, 56, and 52%, respectively. In addition, low doses of tadalafil and vardenafil induced the protein expression of CYP2E1. On the other hand, high doses of either tadalafil or sildenafil were more potent inhibitors to CYP2E1 expression than vardenafil. Moreover, low doses of both vardenafil and sildenafil markedly increased AHH activity by 162 and 247%, respectively, whereas high doses of tadalafil, vardenafil, and sildenafil inhibited such activity by 36, 49, and 57% and inhibited the EROD activity by 39, 49, and 33%, respectively. Low and high doses of tadalafil, vardenafil, and sildenafil inhibited the activity of NADPH‐cytochrome c reductase as well as its protein expression. In addition, such drugs inhibited the expression of CYP B1/2 along with its corresponding enzyme marker ECOD activity. It is concluded that changes in the expression and activity of phase I drug‐metabolising enzymes could change the normal metabolic pathways and might enhance the deleterious effects of exogenous as well as endogenous compounds.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2016/4970906

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 58

  1. 10.1007/s00345-005-0021-7 · DOI
  2. 10.2174/138161209789206971 · DOI
  3. Douglass M. A., 2010, Erectile dysfunction and premature ejaculation: underlying causes and available treatments, Clinical Pharmacology Formulary Journal, 45, 17
  4. 10.1111/j.1743-6109.2011.02504.x · DOI
  5. 10.1016/j.pharmthera.2012.12.007 · DOI · Paper page
  6. 10.2174/1389200003339117 · DOI
  7. 10.1007/s10565-011-9198-2 · DOI
  8. 10.1021/tx400139p · DOI
  9. 10.2174/138920111795470994 · DOI · Paper page
  10. 10.1517/17425255.2013.795219 · DOI
  11. 10.1038/jid.2012.259 · DOI
  12. 10.3109/03602530903286476 · DOI
  13. Huang S. A., 2013, Phosphodiesterase-5 (PDE5) inhibitors in the management of erectile dysfunction, Pharmacology & Therapeutics, 38, 407
  14. 10.1124/dmd.107.020099 · DOI
  15. 10.1016/S0021-9258(19)52451-6 · DOI · Paper page
  16. 10.1016/S0021-9258(20)82244-3 · DOI · Paper page
  17. 10.1016/S0021-9258(18)93967-0 · DOI
  18. 10.1016/0024-3205(68)90217-8 · DOI
  19. Mostafa M., 1992, Modification of the oxidative N-demethylation of dimethylnitrosamine by various anti-inflammatory drugs, Ramazzini Newsletters, 2, 15
  20. 10.1016/0006-2952(75)90028-3 · DOI
  21. Greenlee W. F., 1978, An improved assay of 7-ethoxycoumarin O-deethylase activity: induction of hepatic enzyme activity in C57BL/6J and DBA/2J mice by phenobarbital, 3-methylcholanthrene and 2,3,7,8-tetrachlorodibenzo-p-dioxin, Journal of Pharmacology and Experimental Therapeutics, 205, 596, 10.1016/S0022-3565(25)31268-1 · DOI · Paper page
  22. 10.1016/0003-2697(80)90505-9 · DOI · Paper page
  23. 10.2174/1389200033336919 · DOI
  24. 10.1016/S0300-483X(03)00252-X · DOI
  25. 10.1159/000324289 · DOI
  26. Ye Q., 2012, Cytochrome P450 2E1 inhibition prevents hepatic carcinogenesis induced by diethylnitrosamine in alcohol-fed rats, Hepatobiliary Surgery and Nutrition, 1, 5
  27. 10.1016/j.jhep.2012.08.018 · DOI · Paper page
  28. 10.1093/carcin/13.12.2467 · DOI
  29. 10.1093/carcin/15.2.349 · DOI
  30. 10.1021/tx100081p · DOI
  31. Tsay J. J., 2013, Aryl hydrocarbon receptor and lung cancer, Anticancer Research, 33, 1247
  32. 10.1158/1538-7445.am10-3471 · DOI
  33. Chen J. X., 2014, Rapid induction and progression of PhIP+ DSS- induced colon carcinogenesis in CYP1A-humanized mice, Cancer Research, 74
  34. 10.1016/j.mrgentox.2012.09.008 · DOI
  35. 10.5897/ajb2013.12881 · DOI
  36. 10.1093/carcin/13.9.1513 · DOI
  37. 10.1007/s10529-004-3738-2 · DOI
  38. 10.1080/15287399209531652 · DOI
  39. 10.1080/01635589209514197 · DOI
  40. Koul A., 2005, Modulatory effects of different doses of alpha-tocopherol on benzo (a)pyrene-DNA adduct formation in the pulmonary tissue of cigarette smoke inhaling mice, Indian Journal of Experimental Biology, 43, 1139
  41. 10.1615/jenvpathtoxoncol.v24.i2.70 · DOI
  42. 10.1016/0006-2952(94)90363-8 · DOI · Paper page
  43. 10.1158/1538-7445.AM2012-4427 · DOI
  44. 10.1158/1541-7786.MCR-12-0675 · DOI
  45. 10.1016/j.pharmthera.2010.01.009 · DOI
  46. 10.3390/molecules181214470 · DOI
  47. 10.1515/dmdi-2012-0027 · DOI
  48. Pentyala S., 2011, Pharmacokinetic drug interactions of phosphodiesterase-5 inhibitors mediated by cytochrome P450 3A4 isoform, International Journal of Medicine and Medical Sciences, 3, 22
  49. 10.1177/0091270005276847 · DOI · Paper page
  50. 10.1016/j.clpt.2004.09.006 · DOI
  51. 10.1046/j.0306-5251.2001.00029.x · DOI
  52. 10.1021/bi9715627 · DOI
  53. Lin Y., 2001, Substrate inhibition kinetics for cytochrome P450-catalyzed reactions, Drug Metabolism and Disposition, 29, 368
  54. 10.1002/bies.200900167 · DOI · Paper page
  55. 10.1007/s00726-010-0743-8 · DOI
  56. 10.1042/bj20040062 · DOI
  57. 10.1152/physrev.00021.2011 · DOI · Paper page
  58. 10.1096/fj.11-188300 · DOI

Cited by

See all 15

Metadata

Authors
Sheweita, S. A., Wally, M., & Hassan, M.
ORCID
Venue
Oxidative Medicine and Cellular Longevity
Publisher
Wiley
Published
2016-01
Volume
2016
Issue
1
ISSN
  • 1942-0900
  • 1942-0994
DOI
10.1155/2016/4970906
Cited by
15
References
1
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor, 282 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Erectile Dysfunction Drugs Changed the Protein Expressions and Activities of Drug-Metabolising Enzymes in the Liver of Male Rats. https://app.cochat.ai/papers/10.1155/2016/4970906
The paper
Sheweita, S. A., Wally, M., & Hassan, M. (2016). Erectile Dysfunction Drugs Changed the Protein Expressions and Activities of Drug-Metabolising Enzymes in the Liver of Male Rats. Oxidative Medicine and Cellular Longevity. https://doi.org/10.1155/2016/4970906

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.